WuXi XDC Cayman Inc. (HKG:2268)
Hong Kong · Delayed Price · Currency is HKD 58.90
+2.75 (4.90%)
At close: Mar 27, 2026
WuXi XDC Cayman Revenue
In the year 2025, WuXi XDC Cayman had annual revenue of 5.94B CNY with 46.69% growth. WuXi XDC Cayman had revenue of 3.24B in the half year ending December 31, 2025, with 186.93% growth.
Revenue
5.94B CNY
Revenue Growth
+46.69%
P/S Ratio
11.20
Revenue / Employee
2.62M CNY
Employees
2,270
Market Cap
74.10B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.94B | 1.89B | 46.69% |
| Dec 31, 2024 | 4.05B | 1.93B | 90.80% |
| Dec 31, 2023 | 2.12B | 1.13B | 114.44% |
| Dec 31, 2022 | 990.42M | 679.29M | 218.33% |
| Dec 31, 2021 | 311.13M | 214.78M | 222.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Adicon Holdings | 2.94B |
| Kindstar Globalgene Technology | 998.42M |
| Yunkang Group | 706.95M |
| Biosino Bio-Technology and Science Incorporation | 246.61M |
| Guanze Medical Information Industry (Holding) | 161.70M |
| Mega Genomics | 151.45M |
| King International Investment | 77.50M |
| China Biotech Services Holdings | 76.93M |
WuXi XDC Cayman News
- 12 days ago - US reshoring drive casts shadow over China’s contract drug makers: analyst - South China Morning Post